Skip to content

Based on microRNA199-TRPV1, the intervention mechanism of acupuncture of regulationg the mind and strenthening the sleepen treatment on visceral hypersensitivity in IBS-D patients

Based on microRNA199-TRPV1, the intervention mechanism of acupuncture of regulationg the mind and strenthening the sleepen treatment on visceral hypersensitivity in IBS-D patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17010860
Enrollment
Unknown
Registered
2017-03-14
Start date
2017-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iriitable Bowel Syndrome

Interventions

acupuncture of regulating the mind and strenthening the sleepen group:acupuncture of regulating the mind and strenthening the sleepen

Sponsors

Jiangsu Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) IBS-D Rome III diagnostic criteria; (2) Age is 18-70 years old; (3) lack of morphological changes and biochemical abnormalities that can explain symptoms; (4) Baseline IBS-SSS integral = 75 points; (5) did not use any treatment of IBS at least 2 weeks before treatment (except for emergency treatment), and did not receive acupuncture treatment against IBS for nearly three months; (6) did not participate in other ongoing clinical researchers; (7) signed informed consent, voluntary participation in the study

Exclusion criteria

Exclusion criteria: (1) intestinal organic disease, or affect the digestive tract of the systemic diseases (such as gallbladder pancreatitis, hyperthyroidism, diabetes, chronic renal insufficiency, neurological disease); (2) combined with the cardiovascular system, liver, kidney, hematopoietic system, mental illness, cognitive dysfunction and other serious primary disease; (3) a history of abdominal or rectal surgery; (4) often taking the effect of gastrointestinal motility or change the intestinal function of drugs or preparations; (5) the age of 18 years of age or older; (6) pregnancy, lactation, postpartum = 12 months and allergies; (7) the use of other treatment or taking other drugs, affect the efficacy or safety of those who judge; (8) patients refused to observe the group or contain other unstable factors, such as: not taking the provisions of other effects of observation of the drug can not determine the efficacy or incomplete information; (9) the installation of pacemakers, metal allergies or severe fear of the needle;

Design outcomes

Primary

MeasureTime frame
Colon tissue TRPV1 protein concentration;microRNA-199;

Countries

China

Contacts

Public ContactPei Lixia

Jiangsu Provincial Hospital of TCM

njpeilixia@qq.com+86 18652098600

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026